[Treatment of the edemato-ascitic syndrome with an injectable aldosterone antagonist: 8109 CB].
D000328:Adult; D000368:Aged; D000731:Androstanes / Q000627:therapeutic use*; D001201:Ascites / Q000188:drug therapy*; D004232:Diuretics / Q000008:administration & dosage*; D004487:Edema / Q000188:drug therapy*; D005260:Female; D006333:Heart Failure / Q000150:complications; D006801:Humans; D006914:Hydroxysteroids / Q000627:therapeutic use; D007267:Injections; D007664:Ketosteroids / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D009369:Neoplasms / Q000150:complications; D011422:Propionates / Q000627:therapeutic use
D000731:Androstanes; D004232:Diuretics; D006914:Hydroxysteroids; D007664:Ketosteroids; D000451:Mineralocorticoid Receptor Antagonists; D011422:Propionates
Traitement du syndrome oedémato-ascitique par une anti-aldostérone injectable: le 8109 C.